rhBMP-2

BIOLOGICAL4 trials

Sponsors

Universitaire Ziekenhuizen KU Leuven, Lindenhofgruppe AG, University of Baghdad, Xijing Hospital

Conditions

Blood DiseaseDegenerative Disc DiseaseDiabetes MellitusHypertensionOsteoporosisPseudarthrosisSpinal FusionSpondylolisthesis

Phase 1

Effect of Recombinant Human Bone Morphogenetic Protein-2 With an Absorbable Collagen Sponge on Stability of Dental Implant: (Split Mouth Randomized Clinical Trial Study.

University of BaghdadBlood Disease, Diabetes Mellitus, Hypertension

Start: 2021-12-06End: 2023-04-20Target: 32Updated: 2023-02-08

Unknown Phase

rhBMP-2 vs Autologous Bone Grafting for the Treatment of Non-union of the Docking Site in Tibial Bone Transport

Universitaire Ziekenhuizen KU LeuvenPseudarthrosis

Start: 2015-07-31End: 2016-04-30Target: 20Updated: 2015-05-28

Comparison of Radiographic Fusion Rate and Clinical Outcome of ALIF and XLIF Performed With Either Recombinant Human Bone Morphogenetic Protein-2 or ViviGen®

RecruitingNCT05238740

Lindenhofgruppe AGDegenerative Disc Disease, Spondylolisthesis, Spondylosis

Start: 2022-10-27End: 2032-12-01Target: 168Updated: 2026-08-26

Recombinant Human Bone Morphogenetic Protein-2(rhBMP-2) in Patients With Osteoporosis After Lumbar Fusion

Xijing HospitalOsteoporosis, Spinal Fusion

Start: 2023-07-01End: 2024-06-30Target: 76Updated: 2023-06-22

Related Papers

Recombinant Human Bone Morphogenetic Protein-2 as Bone Additive and its Relation with the Dental Implant Dimensions and Stability: Split-Mouth Randomized Clinical Trial

Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 )2023-10-111 citations